CD274 and neoplasm: In summary, a novel CD16/PD-L1 bi-specific aptamer named CP-bi-apt was developed for cancer immunotherapy that integrates the functions of immune checkpoint blockade and the recruitment of NK cells to tumor site without any additional procedures.